A Multipart, Open-label Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir With and Without Dasabuvir Coadministered With and Without Ribavirin in Adults With Genotype 1 or 4 Chronic Hepatitis C Virus Infection and Human Immunodeficiency Virus, Type 1 Coinfection (TURQUOISE-I).
Latest Information Update: 11 Jun 2019
At a glance
- Drugs Dasabuvir (Primary) ; Ombitasvir/paritaprevir/ritonavir (Primary) ; Ribavirin
- Indications Hepatitis C; HIV-1 infections
- Focus Registrational; Therapeutic Use
- Acronyms TURQUOISE-I
- Sponsors AbbVie; Genentech
- 18 Mar 2017 Results (n=22) presented at the 118th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
- 14 Mar 2017 Results (n=22) of part Ib assessing the efficacy and safety of OBV/PTV/r + DSV with RBV in patients with HCV GT1/HIV-1 coinfection on a stable, DRV-containing ART regimen, published in the Journal of Infectious Diseases
- 05 Dec 2016 Results of a pharmacokinetic substudy (n=22), published in the Antimicrobial Agents and Chemotherapy